Main Publications
2024
NBAtlas: A harmonized single-cell transcriptomic reference atlas of human neuroblastoma tumors.
Bonine N., Zanzani V., Van Hemelryk A., Vanneste B., Zwicker C., Thoné T., Roelandt S., Bekaert S., Koster J., Janoueix-Lerosey I., Thirant C., Van Haver S., Roberts S., Mus L., De Wilde B., Van Roy N., Everaert C., Speleman F., Vermeirssen V., Scott C. & De Preter K. Cell Reports, (2024). DOI: 10.1016/j.celrep.2024.114804, PMID: 39368085
5’UTR translational inhibition of neuroblastoma dependency factors using the CR-1-31-B rocaglate.
Nunes C., Bekaert S., Parsa S., Nelen I., Martens F., De Stanchina E., Sanders E., Hilgert E., T'sas S., Zhao P, De Vloed F., Eggermont A., Goossens S., Sablina A., Depestel L., Wendel HG. & Durinck K. BioRxiv, (2024). DOI: 10.1101/2024.08.29.610236, PMID: /
DNA repair and replicative stress addiction in neuroblastoma.
Durinck K. & Irwin M. S. EJC Paediatric Oncology, (2024). DOI: 10.1016/j.ejcped.2024.100177, PMID: /
MOXD1 is a lineage-specific gene and a tumor suppressor in neuroblastoma.
Fredlund E, Andersson S, Hilgert E, Monferrer E, Álvarez-Hernán G, Karakaya S, Loontiens S, Bek JW, Gregor T, Lecomte E, Magnusson E, Miltenyte E, Cabirol M, Kyknas M, Engström N, Henriksson MA, Hammarlund E, Rosenblum JS, Noguera R, Speleman F, van Nes J, Mohlin S. Science Advances (2024). DOI: 10.1126/sciadv.ado1583, PMID: 38905335
The fork restart factor PHF6 interacts with RRM2 and binds to H3K56ac marked nascent DNA.
Depestel L., Bekaert S., Sanders E., Van Damme C., Eggermont A., Loontiens S., Tilleman L., Van Nieuwerburgh F., Delhaye L., Van Vlierberghe P., Eyckerman S., Speleman F. & Durinck K. BioRxiv, (2024). DOI: 10.1101/2023.03.08.531704, PMID: /
Human iPSC modeling recapitulates in vivo sympathoadrenal development and reveals an aberrant developmental subpopulation in familial neuroblastoma.
Van Haver S., Fan Y., Bekaert S., Everaert C., Van Loocke W., Zanzani V., Deschildre J., Maestre I. F., Amaro A., Vermeirssen V., De Preter K., Zhou T., Kentsis A., Studer L., Speleman F. & Roberts S.S. IScience, (2024). DOI: 10.1016/j.isci.2023.108096, PMID: 38222111
HTSplotter: An end-to-end data processing, analysis and visualisation tool for chemical and genetic in vitro perturbation screening.
Nunes C., Anckaert J, De Vloed F., De Wyn J., Durinck K., Vandesompele J., Speleman F., Vermeirssen V. PLoS One, (2024). DOI: 10.1371/journal.pone.0296322, PMID: 38181013
Bonine N., Zanzani V., Van Hemelryk A., Vanneste B., Zwicker C., Thoné T., Roelandt S., Bekaert S., Koster J., Janoueix-Lerosey I., Thirant C., Van Haver S., Roberts S., Mus L., De Wilde B., Van Roy N., Everaert C., Speleman F., Vermeirssen V., Scott C. & De Preter K. Cell Reports, (2024). DOI: 10.1016/j.celrep.2024.114804, PMID: 39368085
5’UTR translational inhibition of neuroblastoma dependency factors using the CR-1-31-B rocaglate.
Nunes C., Bekaert S., Parsa S., Nelen I., Martens F., De Stanchina E., Sanders E., Hilgert E., T'sas S., Zhao P, De Vloed F., Eggermont A., Goossens S., Sablina A., Depestel L., Wendel HG. & Durinck K. BioRxiv, (2024). DOI: 10.1101/2024.08.29.610236, PMID: /
DNA repair and replicative stress addiction in neuroblastoma.
Durinck K. & Irwin M. S. EJC Paediatric Oncology, (2024). DOI: 10.1016/j.ejcped.2024.100177, PMID: /
MOXD1 is a lineage-specific gene and a tumor suppressor in neuroblastoma.
Fredlund E, Andersson S, Hilgert E, Monferrer E, Álvarez-Hernán G, Karakaya S, Loontiens S, Bek JW, Gregor T, Lecomte E, Magnusson E, Miltenyte E, Cabirol M, Kyknas M, Engström N, Henriksson MA, Hammarlund E, Rosenblum JS, Noguera R, Speleman F, van Nes J, Mohlin S. Science Advances (2024). DOI: 10.1126/sciadv.ado1583, PMID: 38905335
The fork restart factor PHF6 interacts with RRM2 and binds to H3K56ac marked nascent DNA.
Depestel L., Bekaert S., Sanders E., Van Damme C., Eggermont A., Loontiens S., Tilleman L., Van Nieuwerburgh F., Delhaye L., Van Vlierberghe P., Eyckerman S., Speleman F. & Durinck K. BioRxiv, (2024). DOI: 10.1101/2023.03.08.531704, PMID: /
Human iPSC modeling recapitulates in vivo sympathoadrenal development and reveals an aberrant developmental subpopulation in familial neuroblastoma.
Van Haver S., Fan Y., Bekaert S., Everaert C., Van Loocke W., Zanzani V., Deschildre J., Maestre I. F., Amaro A., Vermeirssen V., De Preter K., Zhou T., Kentsis A., Studer L., Speleman F. & Roberts S.S. IScience, (2024). DOI: 10.1016/j.isci.2023.108096, PMID: 38222111
HTSplotter: An end-to-end data processing, analysis and visualisation tool for chemical and genetic in vitro perturbation screening.
Nunes C., Anckaert J, De Vloed F., De Wyn J., Durinck K., Vandesompele J., Speleman F., Vermeirssen V. PLoS One, (2024). DOI: 10.1371/journal.pone.0296322, PMID: 38181013
2023
SOX11 regulates SWI / SNF complex components as member of the adrenergic neuroblastoma core regulatory circuitry.
Decaesteker B., Louwagie A., Loontiens S., De Vloed F. , Bekaert S., Roels J., Vanhauwaert S., De Brouwer S., Sanders E., Berezovskaya A., Denecker G., Eva D., Van Haver S., Van Loocke W., Van Dorpe J., Creytens D., Van Roy N., Pieters T., Van Neste C., Fischer M., Van Vlierberghe P., Roberts S.S., Schulte J., Ek S., Versteeg R., Koster J., Van Nes J., Zimmerman M, De Preter K. & Speleman F. Nature Communications, (2023). DOI: 10.1038/s41467-023-36735-2, PMID: 36882421
Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma.
Rishfi M., Krols S., Martens F., Bekaert S., Sanders E., Eggermont A., De Vloed F., Goulding J., Risseeuw M., Molenaar J., De Wilde B., Van Calenbergh S., & Durinck K. European Journal of Medicinal Chemistry, (2023). DOI: 10.1016/j.ejmech.2022.115033, PMID: 36549117
Decaesteker B., Louwagie A., Loontiens S., De Vloed F. , Bekaert S., Roels J., Vanhauwaert S., De Brouwer S., Sanders E., Berezovskaya A., Denecker G., Eva D., Van Haver S., Van Loocke W., Van Dorpe J., Creytens D., Van Roy N., Pieters T., Van Neste C., Fischer M., Van Vlierberghe P., Roberts S.S., Schulte J., Ek S., Versteeg R., Koster J., Van Nes J., Zimmerman M, De Preter K. & Speleman F. Nature Communications, (2023). DOI: 10.1038/s41467-023-36735-2, PMID: 36882421
Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma.
Rishfi M., Krols S., Martens F., Bekaert S., Sanders E., Eggermont A., De Vloed F., Goulding J., Risseeuw M., Molenaar J., De Wilde B., Van Calenbergh S., & Durinck K. European Journal of Medicinal Chemistry, (2023). DOI: 10.1016/j.ejmech.2022.115033, PMID: 36549117
2022
RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition.
Nunes C.*, Depestel L.*, Mus L., Keller K. M., Delhaye L., Louwagie A., Rishfi M., Whale A., Kara N., Andrews S. R., dela Cruz F., You D., Siddiquee A., Cologna C. T., de Craemer S., Dolman E., Bartenhagen C., de Vloed F., Sanders E., Eggermont A., Bekaert S., Van Loocke W., Bek J. W., Dewyn G., Loontiens S., Van Isterdael G., Decaesteker B., Tilleman L., Van Nieuwerburgh F., Vermeirssen V., Van Neste C., Ghesquire B., Goossens S., Eyckerman S., De Peter K., Fischer M., Houseley J., Molenaar J., De Wilde B., Roberts S.S., Durinck K.*, & Speleman, F*. Science Advances, (2022). DOI = 10.1126/SCIADV.ABN1382, PMID: 35857500
Cellular senescence in neuroblastoma.
Zanotti S., Decaesteker B., Vanhauwaert S., De Wilde B., De Vos W. H. & Speleman F. Britisch Journal of Cancer, (2022). DOI = 10.1038/s41416-022-01755-0, PMID: 35197583
Nunes C.*, Depestel L.*, Mus L., Keller K. M., Delhaye L., Louwagie A., Rishfi M., Whale A., Kara N., Andrews S. R., dela Cruz F., You D., Siddiquee A., Cologna C. T., de Craemer S., Dolman E., Bartenhagen C., de Vloed F., Sanders E., Eggermont A., Bekaert S., Van Loocke W., Bek J. W., Dewyn G., Loontiens S., Van Isterdael G., Decaesteker B., Tilleman L., Van Nieuwerburgh F., Vermeirssen V., Van Neste C., Ghesquire B., Goossens S., Eyckerman S., De Peter K., Fischer M., Houseley J., Molenaar J., De Wilde B., Roberts S.S., Durinck K.*, & Speleman, F*. Science Advances, (2022). DOI = 10.1126/SCIADV.ABN1382, PMID: 35857500
Cellular senescence in neuroblastoma.
Zanotti S., Decaesteker B., Vanhauwaert S., De Wilde B., De Vos W. H. & Speleman F. Britisch Journal of Cancer, (2022). DOI = 10.1038/s41416-022-01755-0, PMID: 35197583
2021
From DNA Copy Number Gains and Tumor Dependencies to Novel Therapeutic Targets for High-Risk Neuroblastoma.
Decaesteker B., Durinck K., van Roy N., de Wilde B., van Neste C., van Haver S., Roberts S.S., de Preter K., Vermeirssen V. & Speleman F. Journal of Personalized Medicine, (2021). DOI = 10.3390/JPM11121286, PMID: 34945759
MEIS2 is an adrenergic core regulatory transcription factor involved in early initiation of TH‐MYCN‐driven neuroblastoma formation.
de Wyn J., Zimmerman M. W., Weichert‐leahey N., Nunes C., Cheung B. B., Abraham B. J., Beckers A., Volders P. J., Decaesteker B., Carter D. R., Look A. T., de Preter K., van Loocke W., Marshall G. M., Durbin A. D., Speleman F., & Durinck K. (2021). Cancers, (2021). DOI = 10.3390/cancers13194783, PMID: 25210800
MYCN-induced nucleolar stress drives an early senescence-like transcriptional program in hTERT-immortalized RPE cells.
Zanotti S., Vanhauwaert S., van Neste C., Olexiouk V., van Laere J., Verschuuren M., van der Meulen J., Mus L. M., Durinck K., Tilleman L., Deforce D., van Nieuwerburgh F., Hogarty M. D., Decaesteker B., de Vos W. H. & Speleman F. (2021). Scientific Reports, (2021). DOI = 10.1038/s41598-021-93863-9, PMID: 34262099
Decaesteker B., Durinck K., van Roy N., de Wilde B., van Neste C., van Haver S., Roberts S.S., de Preter K., Vermeirssen V. & Speleman F. Journal of Personalized Medicine, (2021). DOI = 10.3390/JPM11121286, PMID: 34945759
MEIS2 is an adrenergic core regulatory transcription factor involved in early initiation of TH‐MYCN‐driven neuroblastoma formation.
de Wyn J., Zimmerman M. W., Weichert‐leahey N., Nunes C., Cheung B. B., Abraham B. J., Beckers A., Volders P. J., Decaesteker B., Carter D. R., Look A. T., de Preter K., van Loocke W., Marshall G. M., Durbin A. D., Speleman F., & Durinck K. (2021). Cancers, (2021). DOI = 10.3390/cancers13194783, PMID: 25210800
MYCN-induced nucleolar stress drives an early senescence-like transcriptional program in hTERT-immortalized RPE cells.
Zanotti S., Vanhauwaert S., van Neste C., Olexiouk V., van Laere J., Verschuuren M., van der Meulen J., Mus L. M., Durinck K., Tilleman L., Deforce D., van Nieuwerburgh F., Hogarty M. D., Decaesteker B., de Vos W. H. & Speleman F. (2021). Scientific Reports, (2021). DOI = 10.1038/s41598-021-93863-9, PMID: 34262099
2020
Recurrent chromosomal imbalances provide selective advantage to human embryonic stem cells under enhanced replicative stress conditions.
Mus L., van Haver S., Popovic M., Trypsteen W., Lefever S., Zeltner N., Ogando Y., Jacobs E., Denecker G., Sanders E., van Neste C., Vanhauwaert S., Decaesteker B., Deforce D., van Nieuwerburgh F., Mestdagh P., Vandesompele J., Menten B., de Preter K., Studer L., Heindryckx B., Durinck K., Roberts S.S. & Speleman F. Genes Chromosomes and Cancer, (2020). DOI = 10.1002/gcc.22931, PMID: 33336840
PHF6 Expression Levels Impact Human Hematopoietic Stem Cell Differentiation.
Loontiens S., Dolens A. C., Strubbe S., van de Walle I., Moore F. E., Depestel L., Vanhauwaert S., Matthijssens F., Langenau D. M., Speleman F., van Vlierberghe P., Durinck K. & Taghon T. Frontiers in Cell and Developmental Biology (2020). DOI =10.3389/fcell.2020.599472, PMID: 33251223
A novel TLX1-driven T-ALL zebrafish model: comparative genomic analysis with other leukemia models.
Loontiens S., Vanhauwaert S., Depestel L., Dewyn G., van Loocke W., Moore F. E., Garcia E. G., Batchelor L., Borga C., Squiban B., Malone-Perez M., Volders P. J., Olexiouk V., van Vlierberghe P., Langenau D. M., Frazer J. K., Durinck K., & Speleman F. Leukemia, (2020). DOI = 10.1038/s41375-020-0938-2, PMID: 32591643
The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness.
Mus L. M., Lambertz I., Claeys S., Kumps C., van Loocke W., van Neste C., Umapathy G., Vaapil M., Bartenhagen C., Laureys G., de Wever O., Bexell D., Fischer M., Hallberg B., Schulte J., de Wilde B., Durinck K., Denecker G., de Preter K. & Speleman F. Scientific Reports, (2020). DOI = 10.1038/s41598-019-57076-5, PMID: 31937834
Mus L., van Haver S., Popovic M., Trypsteen W., Lefever S., Zeltner N., Ogando Y., Jacobs E., Denecker G., Sanders E., van Neste C., Vanhauwaert S., Decaesteker B., Deforce D., van Nieuwerburgh F., Mestdagh P., Vandesompele J., Menten B., de Preter K., Studer L., Heindryckx B., Durinck K., Roberts S.S. & Speleman F. Genes Chromosomes and Cancer, (2020). DOI = 10.1002/gcc.22931, PMID: 33336840
PHF6 Expression Levels Impact Human Hematopoietic Stem Cell Differentiation.
Loontiens S., Dolens A. C., Strubbe S., van de Walle I., Moore F. E., Depestel L., Vanhauwaert S., Matthijssens F., Langenau D. M., Speleman F., van Vlierberghe P., Durinck K. & Taghon T. Frontiers in Cell and Developmental Biology (2020). DOI =10.3389/fcell.2020.599472, PMID: 33251223
A novel TLX1-driven T-ALL zebrafish model: comparative genomic analysis with other leukemia models.
Loontiens S., Vanhauwaert S., Depestel L., Dewyn G., van Loocke W., Moore F. E., Garcia E. G., Batchelor L., Borga C., Squiban B., Malone-Perez M., Volders P. J., Olexiouk V., van Vlierberghe P., Langenau D. M., Frazer J. K., Durinck K., & Speleman F. Leukemia, (2020). DOI = 10.1038/s41375-020-0938-2, PMID: 32591643
The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness.
Mus L. M., Lambertz I., Claeys S., Kumps C., van Loocke W., van Neste C., Umapathy G., Vaapil M., Bartenhagen C., Laureys G., de Wever O., Bexell D., Fischer M., Hallberg B., Schulte J., de Wilde B., Durinck K., Denecker G., de Preter K. & Speleman F. Scientific Reports, (2020). DOI = 10.1038/s41598-019-57076-5, PMID: 31937834